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The study by Maisel et al. (1) on the use of B-type
natriuretic peptide (BNP) in the diagnosis of heart failure
(HF) in this issue of the Journal provides additional data and
analyses from the previously published Breathing Not Prop-
erly trial (2). The most important of these, and the focus of
this editorial comment, deal with the 37% of patients (165
of 452 patients) adjudicated to have HF and who had
ejection fractions 45%. Before discussing these results and
their implications, it is important to provide some back-
ground about this group of patients, who are variously
referred to as having “HF with preserved systolic function”
(HFPSF) or “nonsystolic HF” but who for the most part
have HF due to diastolic dysfunction.
See page 2010
IMPORTANCE OF HFPSF
The occurrence of HF in patients without apparent systolic
dysfunction, in the absence of specific conditions such as
valvular abnormalities, infiltrative diseases, or high output
states, initially surprised and continues to confound many
clinicians. When noninvasive cardiac imaging first became
available, this syndrome was considered an oddity. Only
recently has the high prevalence of HFPSF (a designation
that has been loosely applied to patients with ejection
fractions 45% or 50%) been fully appreciated. Various
studies have found 40% to 50% of HF patients to have
normal ejection fractions (3–5). Indeed, in the Cardiovas-
cular Health Study, a community-based longitudinal eval-
uation of individuals 65 years, only a relatively small
minority of patients with heart failure at baseline or who
develop HF during follow-up had ejection fractions 40%,
a value that is often considered a threshold for causing
chronic systolic HF (6).
CHARACTERISTICS OF PATIENTS WITH HFPSF
Who are these patients with heart failure in the absence of
systolic dysfunction? Compared to patients with HF and
reduced ejection fractions, they tend to be older, more
frequently women, and to have a history of hypertension
that persists even after HF develops (3–5,7). Coronary
disease and other manifestations of arteriosclerosis are
common, but fewer have prior myocardial infarctions.
Nonetheless, there is considerable overlap with systolic HF.
Thus, demographic characteristics and accompanying con-
ditions cannot distinguish the underlying physiology in
individual patients with HF.
The clinical presentation of patients with HFPSF and
systolic HF may differ in some aspects, but overlap is again
considerable; HFPSF tends to be more episodic and quickly
responsive to therapy (especially diuretics and treatment of
hypertension and ischemia, if present). When HF is chronic
and relatively severe, systolic dysfunction is more likely.
Aside from persistent and sometimes severe hypertension in
patients with HFPSF, the physical examination also does
not provide discriminating information, with both groups
often having signs of left- and, sometimes, right-sided
failure. Thus, direct measurement of systolic function has
been the only way to differentiate these groups.
MECHANISM OF HFPSF
What is the cause of nonsystolic HF? In the absence of the
type of conditions previously mentioned (valvular heart
disease, high output states), the mechanism in most cases is
diastolic dysfunction (8). Figure 1 schematically illustrates
some of the processes that lead to diastolic dysfunction and
failure. The left ventricle undergoes structural and func-
tional changes as a result of the increased vascular load
presented by hypertension and loss of vascular compliance
and elasticity due to arteriosclerosis, aging, and endothelial
dysfunction. In addition, cardiac aging and, in some pa-
tients, episodic ischemia have direct effects on myocardial
structure and function. These processes result in myocardial
hypertrophy and fibrosis, with loss of myocardial compli-
ance and, in some cases, impaired relaxation. Chronically or
intermittently elevated left ventricular diastolic pressures
then cause the symptoms and signs of HF.
Unfortunately, direct measurements of diastolic function
are invasive and difficult to perform, so they are rarely
available in HF patients. Alternatively, physicians use indi-
rect measurements, based on transvalvular flow patterns
measured by Doppler echocardiography (such as mitral
valve flow velocities and relaxation times), Doppler-derived
indices of cardiac motion, or radionuclide indices of ven-
tricular filling (9). Although noninvasive and readily avail-
able, these techniques have important limitations. Measure-
ments are often rate- and load-dependent, and they vary
with age even in healthy populations (10). Thus, except
when the abnormalities are severe, substantial overlap exists
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between older patients with clinical evidence of diastolic HF
and asymptomatic subjects. Typically, patients with systolic
HF also have diastolic dysfunction, so these measurements
themselves do not distinguish these abnormal physiologies.
The clinical dilemma. When first learning that their
patient with presumed HF has a normal or near normal
ejection fraction, clinicians should ask themselves several
questions. First, is the ejection fraction correct? All mea-
surement techniques, whether quantitative or qualitative,
are fallible, especially when the data are suboptimal. The
distinction between 50% and 39% is not always obvious, but
it is useful because of the demonstrated benefits that
medications such as angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers have been in systolic dysfunc-
tion.
Second, was the diagnosis of HF correct? In the past,
clinicians often, but in many cases incorrectly, excluded the
diagnosis when informed that left ventricular function was
normal. But there are many potentially confounding causes
for the symptoms and signs of HF. Some of these are listed
in Table 1. The answer to this question is important in
determining whether additional diagnostic testing is re-
quired, and it also has therapeutic implications.
Third, was HF precipitated by a transient condition that
may have impaired systolic function that has now resolved,
such as myocardial ischemia, an arrhythmia, or episodic
hypertension? Is further evaluation required?
A simple diagnostic test is needed. In this setting, great
need exists for a simple, readily available, reliable, and
cost-effective diagnostic test. Ideally, the test could answer
three questions: 1) In a patient with symptoms and signs
attributable to HF, whether systolic or diastolic in origin,
will the test be abnormal? In other words, does it have high
sensitivity? 2) Conversely, does an abnormal test in a
symptomatic patient exclude other causes for the clinical
presentation? For example, does the test have high speci-
ficity for the diagnosis? 3) Can the same test distinguish
systolic HF from diastolic HF? A test with these character-
istics would not only facilitate appropriate management but
might also obviate an extensive and expensive evaluation
that often includes repeating previously performed tests and
invasive procedures.
The test most frequently employed to address these
questions is echocardiography with Doppler-flow measure-
ments (echo-Doppler) (9). How well does it fill the need?
Although echo-Doppler is noninvasive and widely available,
it often is not available “on demand,” and it is relatively
expensive. If a technically adequate study can be obtained,
echo-Doppler has high sensitivity. With regard to sensitiv-
ity, a completely normal study, showing normal chamber
size, function, and structure, with normal mitral flow
velocities excludes HF with a high degree of certainty.
However, echo-Doppler is less specific for the diagnosis of
HF. Patients with no evidence of HF may have abnormal-
ities of cardiac function or structure (reduced systolic func-
tion, chamber enlargement or hypertrophy, valvular abnor-
malities, and abnormal diastolic flow patterns), and patients
with these findings may have symptoms and signs consistent
Figure 1. Some of the processes that lead to diastolic dysfunction and heart failure.
Table 1. Potentially Confounding Causes of Symptoms and
Signs Mimicking Heart Failure
Pulmonary causes
Pulmonary disease
Pulmonary emboli
Sleep apnea
Obesity
Anemia
Venous insufficiency
Drug-induced fluid retention
Calcium antagonists
Nonsteroidal anti-inflammatory drugs
Thiazolidinediones
Cirrhosis
Renal failure
Hypoalbuminemia
Thyroid dysfunction
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with HF owing to a noncardiac etiology. And with regard to
the third need, echo-Doppler is the test clinicians depend
upon to distinguish systolic HF from HFPSF. In this
regard, it is the ejection fraction measurement, not mea-
surements of diastolic function, that drives this classifica-
tion. Many patients with HFPSF do not have clear-cut
evidence of diastolic dysfunction.
It should also be noted that the value of echo-Doppler is
not limited to its ability to diagnose or exclude HF. It
provides additional invaluable information on the etiology
of HF. Furthermore, many of the findings that may result in
a false-positive diagnosis of HF are clearly pathological and
may be clinically important, leading to effective interven-
tions (such as ACE inhibitors or beta-blockers for asymp-
tomatic systolic dysfunction, more rigorous treatment of
hypertension, or even valve repair or replacement).
THE ROLE OF NATRIURETIC PEPTIDE
MEASUREMENTS IN THE DIAGNOSIS OF HF
Early results have suggested that natriuretic peptide mea-
surements may fulfill some of these needs (11,12). Atrial
natriuretic peptide (ANP), BNP, and the N-terminal por-
tion of BNP (NT-BNP) levels are all increased in patients
with elevated left ventricular diastolic pressures, and the
latter two are now available commercially as diagnostic tests
for HF. Natriuretic peptides have been shown to be elevated
in patients with HFPSF and in patients with evidence of
diastolic dysfunction (13,14).
The Breathing Not Properly trial provides the largest
multicenter experience with the use of natriuretic peptide
measurements for the diagnosis of HF in 1,586 patients
presenting to an emergency room with a primary complaint
of dyspnea (2). The emergency room physicians made a
clinical determination as to whether the dyspnea was due to
HF or not, and a blood sample was collected for later
determination of BNP levels. The final diagnosis, adjudi-
cated by two independent cardiologists unaware of either
the clinical diagnosis or the BNP measurements, was
dyspnea due to HF in 744 patients (47%), dyspnea due to
other causes in a patient with a history of left ventricular
dysfunction in 72 (5%), and no finding of HF in 770
patients (49%). Using a cut point of 100 pg/ml, the BNP
had a sensitivity of 90%, a specificity of 76%, and an
accuracy of 83% for differentiating HF from other causes of
dyspnea. The BNP was more accurate than any historical or
physical examination variable. Among those with a com-
pleted emergency room diagnosis, the accuracy for the
diagnosis of HF for BNP was 81%, which was superior to
that of the treating clinician (74%) (15).
The performance of BNP in the diagnosis of HFPSF.
The accompanying study by Maisel et al. (1) provides the
first information from the Breathing Not Properly trial
about patients with HFPSF. Using an ejection fraction of
45% to define this group (their mean EF was 59%),
patients with HFPSF constituted 165 (36.5%) of the 452
subjects with an adjudicated diagnosis of HF who had
echocardiograms within 30 days of the emergency room
visit. The median BNP of the HFPSF patients was 413
pg/ml, compared to 34 pg/ml in the patients without HF (p
 0.001) and 821 pg/ml in patients with systolic HF (also
p  0.001). Thus, BNP appears to be a helpful test in
patients with HFPSF.
However, a closer look at the data indicates important
limitations exist to the use of BNP to diagnose HFPSF.
Considerable overlap occurs in BNP levels in HFPSF
patients and those without HF. The sensitivity of BNP at a
threshold of 100 pg/ml remained acceptable at 85%; none-
theless, 15% of HFPSF patients were missed—a figure
substantially higher than in systolic HF. The larger prob-
lem, however, is specificity, and this is driven by the higher
BNP levels exhibited in older patients, and particularly in
older women, whose median BNP without HF was above
the 100 pg/ml cut point. Indeed, no significant difference
was seen in BNP levels between women adjudicated to have
HFPSF and those who did not have HF. This problem is
further compounded by the fact that older women consti-
tute the largest proportion of patients with HFPSF (16,17).
Finally, BNP levels did not separate patients with systolic
HF from those with HFPSF, although the former group
tended to have higher levels.
The poorer performance of BNP in diagnosing HFPSF
is, in fact, not surprising. With regard to its inability to
distinguish systolic from nonsystolic HF, this should be
expected because the symptoms in both conditions relate to
elevated ventricular filling pressures, the mechanism respon-
sible for rising BNP levels. The trend to higher measure-
ments in systolic HF probably relate to the generally greater
chronicity and severity of systolic HF. If this distinction is to
be made, a measure of ejection fraction is required.
The higher BNP levels in older women and, to a lesser
extent, older men probably reflect underlying diastolic
dysfunction in these groups and may well represent the
equivalent of asymptomatic left ventricular systolic dysfunc-
tion; the levels probably identify patients at risk for devel-
oping diastolic HF (16,18–20). Indeed, the same phenom-
enon is responsible for the relatively poor specificity of
Doppler-derived indices of diastolic filling for the diagnosis
of HFPSF. The use of age and gender-specific “normal”
values would improve the specificity of the test, but with a
loss of sensitivity, which is already lower for HFPSF and
systolic HF. Rather, clinicians will continue to have to use
a Bayesian approach to the diagnosis of HFPSF, carefully
considering the likelihood that the patient has HF and
using elevated natriuretic peptide levels as corroborative
evidence.
Study implications. Natriuretic peptides are becoming an
important adjunct to the diagnosis of HF. They are highly
accurate for the diagnosis of systolic HF, but unfortunately
perform less well for HFPSF. It is important to recognize
that natriuretic peptide levels increase with age, especially in
women, probably as a result of the changes in cardiac
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structure and diastolic function with aging in industrialized
societies. Thus, a higher rate of false-positive results is to be
expected. An elevated BNP measurement in these demo-
graphic groups should be interpreted in light of the clinical
presentation, and an echocardiogram may be necessary to
clarify the diagnosis. Unfortunately, natriuretic peptides
cannot differentiate systolic from diastolic HF, thus, a
measurement of ejection fraction is still required to guide
the management, if not necessarily the diagnosis, of this
syndrome.
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